Concepts (260)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Multiplex Polymerase Chain Reaction | 7 | 2021 | 1439 | 1.66 | Why? |
| Drug Resistance, Viral | 9 | 2021 | 1083 | 1.26 | Why? |
| HIV Protease | 6 | 2019 | 86 | 0.92 | Why? |
| HIV-2 | 3 | 2018 | 92 | 0.91 | Why? |
| HIV-1 | 10 | 2020 | 3365 | 0.75 | Why? |
| Hyaluronan Receptors | 1 | 2018 | 61 | 0.72 | Why? |
| Immunomagnetic Separation | 1 | 2018 | 55 | 0.71 | Why? |
| Superinfection | 1 | 2021 | 459 | 0.62 | Why? |
| Virus Cultivation | 1 | 2018 | 579 | 0.55 | Why? |
| Respiratory Tract Infections | 4 | 2021 | 6817 | 0.54 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2021 | 13720 | 0.52 | Why? |
| HIV Infections | 10 | 2020 | 11620 | 0.46 | Why? |
| Virus Diseases | 2 | 2021 | 3779 | 0.45 | Why? |
| Antibodies | 1 | 2018 | 846 | 0.44 | Why? |
| HIV Protease Inhibitors | 3 | 2019 | 434 | 0.42 | Why? |
| Seasons | 3 | 2017 | 4071 | 0.41 | Why? |
| France | 14 | 2021 | 12074 | 0.40 | Why? |
| Molecular Diagnostic Techniques | 3 | 2020 | 4239 | 0.39 | Why? |
| Pneumonia, Ventilator-Associated | 1 | 2017 | 861 | 0.38 | Why? |
| gag Gene Products, Human Immunodeficiency Virus | 2 | 2019 | 95 | 0.35 | Why? |
| Viruses | 2 | 2021 | 2238 | 0.34 | Why? |
| Anti-HIV Agents | 6 | 2020 | 2209 | 0.34 | Why? |
| Clinical Laboratory Techniques | 5 | 2021 | 23402 | 0.32 | Why? |
| Epidemiological Monitoring | 1 | 2020 | 3493 | 0.32 | Why? |
| Mutation | 8 | 2021 | 12376 | 0.30 | Why? |
| Genetic Variation | 1 | 2020 | 3919 | 0.29 | Why? |
| Viral Load | 13 | 2021 | 15850 | 0.29 | Why? |
| Furans | 3 | 2020 | 156 | 0.29 | Why? |
| Virus Shedding | 2 | 2021 | 5834 | 0.29 | Why? |
| Immunocompromised Host | 1 | 2021 | 5150 | 0.27 | Why? |
| Darunavir | 2 | 2018 | 477 | 0.27 | Why? |
| Coinfection | 3 | 2021 | 6820 | 0.26 | Why? |
| beta-Cyclodextrins | 2 | 2020 | 87 | 0.26 | Why? |
| Triazines | 2 | 2020 | 246 | 0.23 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 2 | 2021 | 8843 | 0.22 | Why? |
| Pyrroles | 2 | 2020 | 292 | 0.21 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 9335 | 0.19 | Why? |
| Nasopharynx | 6 | 2021 | 10224 | 0.19 | Why? |
| Sensitivity and Specificity | 7 | 2021 | 22971 | 0.19 | Why? |
| APOBEC-3G Deaminase | 1 | 2018 | 33 | 0.19 | Why? |
| Mucosal-Associated Invariant T Cells | 1 | 2021 | 170 | 0.19 | Why? |
| Interleukin-18 | 1 | 2021 | 328 | 0.19 | Why? |
| Genotype | 3 | 2020 | 4697 | 0.18 | Why? |
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2018 | 39 | 0.18 | Why? |
| HIV Envelope Protein gp41 | 1 | 2019 | 153 | 0.18 | Why? |
| Intensive Care Units | 5 | 2020 | 29594 | 0.18 | Why? |
| Respiratory System | 2 | 2020 | 3213 | 0.17 | Why? |
| Alphapapillomavirus | 1 | 2018 | 107 | 0.17 | Why? |
| Picornaviridae | 1 | 2017 | 123 | 0.16 | Why? |
| Paris | 1 | 2021 | 1287 | 0.16 | Why? |
| Healthy Lifestyle | 1 | 2021 | 447 | 0.16 | Why? |
| Emtricitabine | 1 | 2017 | 202 | 0.16 | Why? |
| Cobicistat | 1 | 2017 | 172 | 0.16 | Why? |
| Capsid | 1 | 2017 | 197 | 0.15 | Why? |
| Male | 28 | 2021 | 367725 | 0.15 | Why? |
| DNA Mutational Analysis | 1 | 2018 | 581 | 0.15 | Why? |
| Bone Diseases, Infectious | 1 | 2015 | 20 | 0.15 | Why? |
| Quinolones | 1 | 2017 | 167 | 0.15 | Why? |
| Atazanavir Sulfate | 1 | 2018 | 213 | 0.15 | Why? |
| Virulence | 2 | 2020 | 2172 | 0.15 | Why? |
| Kingella kingae | 1 | 2015 | 15 | 0.15 | Why? |
| Aged | 20 | 2021 | 215776 | 0.15 | Why? |
| Neisseriaceae Infections | 1 | 2015 | 21 | 0.15 | Why? |
| Weight Loss | 1 | 2021 | 826 | 0.15 | Why? |
| Limit of Detection | 2 | 2020 | 2698 | 0.15 | Why? |
| Cross Infection | 1 | 2017 | 8675 | 0.14 | Why? |
| Antiviral Agents | 5 | 2021 | 41703 | 0.14 | Why? |
| Anemia, Sickle Cell | 1 | 2021 | 546 | 0.14 | Why? |
| Humans | 45 | 2021 | 930598 | 0.14 | Why? |
| Adenosine Monophosphate | 3 | 2020 | 5652 | 0.14 | Why? |
| Alanine | 3 | 2020 | 5687 | 0.14 | Why? |
| Treatment Failure | 1 | 2020 | 2106 | 0.13 | Why? |
| Carbamates | 1 | 2018 | 485 | 0.13 | Why? |
| Middle Aged | 21 | 2021 | 270681 | 0.13 | Why? |
| Coronavirus Infections | 10 | 2020 | 253789 | 0.13 | Why? |
| Risk Reduction Behavior | 1 | 2021 | 946 | 0.13 | Why? |
| Pneumonia, Viral | 10 | 2020 | 243684 | 0.13 | Why? |
| Tenofovir | 1 | 2017 | 449 | 0.13 | Why? |
| Betacoronavirus | 9 | 2020 | 204454 | 0.13 | Why? |
| Reagent Kits, Diagnostic | 2 | 2021 | 2149 | 0.13 | Why? |
| Arthritis, Infectious | 1 | 2015 | 111 | 0.13 | Why? |
| Immunoassay | 2 | 2020 | 4485 | 0.13 | Why? |
| Respiratory Syncytial Viruses | 1 | 2017 | 612 | 0.12 | Why? |
| Sexual and Gender Minorities | 2 | 2020 | 1019 | 0.12 | Why? |
| Adult | 19 | 2021 | 244371 | 0.12 | Why? |
| Prevalence | 6 | 2021 | 25773 | 0.12 | Why? |
| Interferon-alpha | 1 | 2021 | 1442 | 0.12 | Why? |
| Hygiene | 1 | 2019 | 987 | 0.12 | Why? |
| Recombination, Genetic | 1 | 2019 | 1265 | 0.12 | Why? |
| Phylogeny | 3 | 2020 | 13341 | 0.12 | Why? |
| Lung Transplantation | 2 | 2020 | 1554 | 0.12 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 1 | 2020 | 1165 | 0.12 | Why? |
| Female | 24 | 2021 | 380317 | 0.12 | Why? |
| Influenza B virus | 1 | 2017 | 815 | 0.11 | Why? |
| Aged, 80 and over | 9 | 2021 | 88759 | 0.11 | Why? |
| Pre-Exposure Prophylaxis | 1 | 2020 | 1138 | 0.11 | Why? |
| Adenoviridae | 1 | 2017 | 1151 | 0.11 | Why? |
| HIV | 1 | 2018 | 1116 | 0.11 | Why? |
| Camelus | 1 | 2019 | 1425 | 0.11 | Why? |
| Sequence Analysis, DNA | 1 | 2020 | 2830 | 0.11 | Why? |
| Point-of-Care Testing | 2 | 2020 | 2782 | 0.10 | Why? |
| DNA, Viral | 2 | 2019 | 2521 | 0.10 | Why? |
| Disease Reservoirs | 1 | 2019 | 1672 | 0.10 | Why? |
| RNA, Viral | 5 | 2021 | 32276 | 0.10 | Why? |
| Methylprednisolone | 1 | 2020 | 2107 | 0.10 | Why? |
| Pneumonia, Bacterial | 1 | 2017 | 843 | 0.10 | Why? |
| Papillomavirus Infections | 1 | 2018 | 861 | 0.10 | Why? |
| High-Throughput Nucleotide Sequencing | 5 | 2019 | 3633 | 0.10 | Why? |
| Picornaviridae Infections | 1 | 2015 | 544 | 0.10 | Why? |
| CD4 Lymphocyte Count | 3 | 2019 | 1517 | 0.09 | Why? |
| Polymerase Chain Reaction | 3 | 2021 | 6740 | 0.09 | Why? |
| Sulfonamides | 1 | 2018 | 1294 | 0.09 | Why? |
| Macrophages | 1 | 2021 | 2784 | 0.09 | Why? |
| Saudi Arabia | 1 | 2019 | 4423 | 0.09 | Why? |
| Influenza A virus | 2 | 2017 | 2234 | 0.09 | Why? |
| Rhinovirus | 1 | 2015 | 979 | 0.09 | Why? |
| Orthomyxoviridae | 1 | 2017 | 1168 | 0.09 | Why? |
| Survival Rate | 2 | 2021 | 9206 | 0.09 | Why? |
| Monocytes | 1 | 2021 | 2978 | 0.09 | Why? |
| Ritonavir | 2 | 2020 | 4212 | 0.09 | Why? |
| Nucleocapsid Proteins | 1 | 2020 | 3120 | 0.09 | Why? |
| Viral Envelope Proteins | 1 | 2020 | 3539 | 0.09 | Why? |
| Patient Isolation | 1 | 2021 | 3182 | 0.08 | Why? |
| Infant | 3 | 2021 | 30274 | 0.08 | Why? |
| Respiratory Syncytial Virus Infections | 1 | 2017 | 1234 | 0.08 | Why? |
| Models, Molecular | 2 | 2019 | 7616 | 0.08 | Why? |
| Enzyme Inhibitors | 1 | 2018 | 1881 | 0.08 | Why? |
| Genome, Viral | 2 | 2019 | 13157 | 0.08 | Why? |
| Diabetes Mellitus, Type 1 | 1 | 2021 | 1969 | 0.08 | Why? |
| Renal Dialysis | 2 | 2020 | 4358 | 0.08 | Why? |
| Adenosine | 2 | 2020 | 509 | 0.08 | Why? |
| Oropharynx | 1 | 2015 | 1581 | 0.08 | Why? |
| Child, Preschool | 3 | 2021 | 36283 | 0.08 | Why? |
| Bacteria | 1 | 2017 | 1897 | 0.08 | Why? |
| Evolution, Molecular | 1 | 2020 | 3691 | 0.08 | Why? |
| Drug Therapy, Combination | 4 | 2020 | 7268 | 0.08 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.07 | Why? |
| Emergency Service, Hospital | 3 | 2020 | 14232 | 0.07 | Why? |
| Symptom Assessment | 1 | 2019 | 4967 | 0.07 | Why? |
| Communicable Diseases, Emerging | 1 | 2019 | 2523 | 0.07 | Why? |
| Glucocorticoids | 1 | 2020 | 4431 | 0.07 | Why? |
| Chiroptera | 1 | 2019 | 3530 | 0.07 | Why? |
| Retrospective Studies | 4 | 2021 | 105322 | 0.07 | Why? |
| Protein Conformation | 3 | 2019 | 4386 | 0.06 | Why? |
| Gene Frequency | 2 | 2018 | 1210 | 0.06 | Why? |
| Prospective Studies | 7 | 2021 | 43301 | 0.06 | Why? |
| Time Factors | 3 | 2021 | 31397 | 0.06 | Why? |
| Amino Acid Sequence | 3 | 2019 | 6049 | 0.06 | Why? |
| Influenza, Human | 2 | 2017 | 10779 | 0.06 | Why? |
| Sequence Alignment | 2 | 2019 | 2109 | 0.06 | Why? |
| Viral Nonstructural Proteins | 1 | 2020 | 4810 | 0.06 | Why? |
| Models, Theoretical | 1 | 2021 | 6659 | 0.06 | Why? |
| Comorbidity | 3 | 2021 | 34796 | 0.06 | Why? |
| Child | 3 | 2021 | 70012 | 0.06 | Why? |
| Young Adult | 4 | 2021 | 93724 | 0.06 | Why? |
| Pharmaceutical Solutions | 1 | 2020 | 24 | 0.06 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 11367 | 0.06 | Why? |
| Disease Management | 1 | 2019 | 6841 | 0.06 | Why? |
| Nutritive Value | 1 | 2021 | 100 | 0.05 | Why? |
| Viremia | 2 | 2019 | 1020 | 0.05 | Why? |
| Risk Factors | 5 | 2021 | 71621 | 0.05 | Why? |
| Extracorporeal Membrane Oxygenation | 1 | 2019 | 5002 | 0.05 | Why? |
| Travel | 1 | 2019 | 7220 | 0.05 | Why? |
| Severity of Illness Index | 4 | 2021 | 48226 | 0.05 | Why? |
| Prognosis | 2 | 2021 | 32490 | 0.05 | Why? |
| Neuroglia | 1 | 2020 | 130 | 0.05 | Why? |
| Obesity | 1 | 2021 | 7388 | 0.05 | Why? |
| Interleukin-15 | 1 | 2021 | 169 | 0.05 | Why? |
| Adolescent | 3 | 2021 | 86841 | 0.05 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2021 | 6166 | 0.05 | Why? |
| Non-Randomized Controlled Trials as Topic | 1 | 2020 | 220 | 0.05 | Why? |
| Pliability | 1 | 2019 | 36 | 0.05 | Why? |
| Epidemics | 1 | 2019 | 6407 | 0.05 | Why? |
| Apolipoproteins B | 1 | 2018 | 47 | 0.05 | Why? |
| Habits | 1 | 2021 | 334 | 0.05 | Why? |
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2020 | 256 | 0.05 | Why? |
| Respiration, Artificial | 2 | 2020 | 22116 | 0.04 | Why? |
| Cohort Studies | 5 | 2021 | 36005 | 0.04 | Why? |
| HIV Integrase | 1 | 2018 | 67 | 0.04 | Why? |
| HIV Reverse Transcriptase | 1 | 2018 | 104 | 0.04 | Why? |
| Viral Vaccines | 1 | 2019 | 7560 | 0.04 | Why? |
| Human papillomavirus 16 | 1 | 2018 | 95 | 0.04 | Why? |
| Case-Control Studies | 3 | 2021 | 17671 | 0.04 | Why? |
| Sequence Analysis, Protein | 1 | 2018 | 309 | 0.04 | Why? |
| Protein Binding | 3 | 2019 | 11430 | 0.04 | Why? |
| Cervix Uteri | 1 | 2018 | 146 | 0.04 | Why? |
| Bronchoalveolar Lavage | 1 | 2021 | 603 | 0.04 | Why? |
| Maintenance Chemotherapy | 1 | 2017 | 133 | 0.04 | Why? |
| Tablets | 1 | 2017 | 219 | 0.04 | Why? |
| HIV Seropositivity | 1 | 2019 | 320 | 0.04 | Why? |
| Hydrogen Bonding | 1 | 2019 | 599 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Pandemics | 12 | 2021 | 389249 | 0.04 | Why? |
| Conserved Sequence | 1 | 2019 | 751 | 0.04 | Why? |
| Weight Gain | 1 | 2021 | 552 | 0.04 | Why? |
| Immunophenotyping | 1 | 2021 | 1290 | 0.04 | Why? |
| Age Factors | 1 | 2017 | 21039 | 0.04 | Why? |
| Global Health | 1 | 2019 | 13911 | 0.04 | Why? |
| Interleukin-1beta | 1 | 2021 | 992 | 0.04 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.04 | Why? |
| Phylogeography | 1 | 2019 | 824 | 0.04 | Why? |
| Anal Canal | 1 | 2018 | 367 | 0.04 | Why? |
| Microbial Interactions | 1 | 2015 | 67 | 0.04 | Why? |
| Protein Subunits | 1 | 2018 | 755 | 0.04 | Why? |
| Interleukin-8 | 1 | 2021 | 964 | 0.04 | Why? |
| Withholding Treatment | 1 | 2020 | 798 | 0.03 | Why? |
| Transplant Recipients | 2 | 2020 | 4982 | 0.03 | Why? |
| Interleukin-10 | 1 | 2021 | 1409 | 0.03 | Why? |
| Ligands | 1 | 2019 | 1300 | 0.03 | Why? |
| Animals | 2 | 2021 | 78931 | 0.03 | Why? |
| Drug Interactions | 1 | 2020 | 1653 | 0.03 | Why? |
| Administration, Oral | 1 | 2020 | 2340 | 0.03 | Why? |
| Hospital Mortality | 1 | 2017 | 22087 | 0.03 | Why? |
| Smoking Cessation | 1 | 2021 | 826 | 0.03 | Why? |
| Switzerland | 1 | 2020 | 2738 | 0.03 | Why? |
| Kinetics | 1 | 2021 | 3238 | 0.03 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2017 | 952 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2020 | 4260 | 0.03 | Why? |
| Bayes Theorem | 1 | 2020 | 3237 | 0.03 | Why? |
| Cluster Analysis | 1 | 2019 | 3001 | 0.03 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.03 | Why? |
| Viral Proteins | 2 | 2020 | 7370 | 0.03 | Why? |
| Single-Cell Analysis | 1 | 2021 | 2450 | 0.03 | Why? |
| Crystallography, X-Ray | 1 | 2018 | 2689 | 0.03 | Why? |
| Multiple Organ Failure | 1 | 2020 | 1724 | 0.03 | Why? |
| Health Surveys | 1 | 2021 | 2841 | 0.02 | Why? |
| Phosphoproteins | 1 | 2020 | 4346 | 0.02 | Why? |
| Microbial Sensitivity Tests | 1 | 2018 | 2886 | 0.02 | Why? |
| Interferons | 1 | 2021 | 2885 | 0.02 | Why? |
| Odds Ratio | 1 | 2020 | 5861 | 0.02 | Why? |
| Whole Genome Sequencing | 1 | 2019 | 3239 | 0.02 | Why? |
| Body Mass Index | 1 | 2021 | 4306 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2020 | 6543 | 0.02 | Why? |
| Critical Illness | 2 | 2021 | 17281 | 0.02 | Why? |
| Binding Sites | 1 | 2019 | 6201 | 0.02 | Why? |
| Diagnostic Tests, Routine | 1 | 2017 | 2643 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2020 | 7220 | 0.02 | Why? |
| Consensus | 1 | 2020 | 6345 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2020 | 9537 | 0.02 | Why? |
| Chronic Disease | 1 | 2019 | 5139 | 0.02 | Why? |
| Vero Cells | 1 | 2021 | 14117 | 0.02 | Why? |
| RNA, Messenger | 1 | 2018 | 5131 | 0.02 | Why? |
| Point-of-Care Systems | 1 | 2017 | 2955 | 0.02 | Why? |
| Drug Discovery | 1 | 2018 | 3092 | 0.02 | Why? |
| Health Behavior | 1 | 2021 | 4449 | 0.02 | Why? |
| Carrier State | 1 | 2015 | 2100 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.02 | Why? |
| Interleukin-6 | 1 | 2021 | 7522 | 0.02 | Why? |
| Algorithms | 1 | 2019 | 7346 | 0.01 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2017 | 11304 | 0.01 | Why? |
| Exercise | 1 | 2021 | 6771 | 0.01 | Why? |
| Population Surveillance | 1 | 2017 | 4967 | 0.01 | Why? |
| Incidence | 1 | 2021 | 25622 | 0.01 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 8811 | 0.01 | Why? |
| Risk Assessment | 1 | 2021 | 25439 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2020 | 21571 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.01 | Why? |
| Disease Outbreaks | 1 | 2019 | 27595 | 0.01 | Why? |